Search results for "Zed"

showing 10 items of 5581 documents

Machine Learning-Based Approach Highlights the Use of a Genomic Variant Profile for Precision Medicine in Ovarian Failure

2021

Ovarian failure (OF) is a common cause of infertility usually diagnosed as idiopathic, with genetic causes accounting for 10–25% of cases. Whole-exome sequencing (WES) may enable identifying contributing genes and variant profiles to stratify the population into subtypes of OF. This study sought to identify a blood-based gene variant profile using accumulation of rare variants to promote precision medicine in fertility preservation programs. A case–control (n = 118, n = 32, respectively) WES study was performed in which only non-synonymous rare variants &lt

0301 basic medicineInfertilityOncologygenomic taxonomymedicine.medical_specialtyprecision medicineovarian failurePopulationMedicine (miscellaneous)BiologyGenoma humàArticlewhole exome sequencing03 medical and health sciences0302 clinical medicineInternal medicinemedicinesingle nucleotide variantFertility preservationeducationGeneExome sequencingeducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryRpersonalized medicinePrecision medicinemedicine.diseaseprediction modelMinor allele frequency030104 developmental biologyGinecologiaMedicineovaryPersonalized medicineinfertilitybusinessgenome variant profileJournal of Personalized Medicine
researchProduct

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

2018

The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. A randomized, double-blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fatty liver disease activity score [NAS] ≥4, and liver fibrosis (stages 1-3, NASH Clinical Research Network) at 81 clinical sites. Subjects (N = 289) were randomly assigned CVC 150 mg or placebo. Primary outcome was ≥2-point improvement in NAS and no worsening of fibrosis at year 1. Key secondary outcomes were: resolution of steatohepatitis and no worsening of fibrosis; improvement in fibrosis by ≥1 stag…

0301 basic medicineLiver CirrhosisMalePlacebo-controlled studyMedical Biochemistry and MetabolomicsGastroenterologyOral and gastrointestinallaw.inventionHepatitisNASH NAFLD CVC nonalcoholic fatty liver inflammationSteatohepatitis/Metabolic Liver Disease0302 clinical medicineRandomized controlled trialFibrosislawNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseeducation.field_of_studyCVCLiver DiseaseNASHImidazolesMiddle AgedTreatment OutcomeTolerabilityLiverSulfoxides6.1 PharmaceuticalsCCR5 Receptor Antagonists030211 gastroenterology & hepatologyOriginal ArticleFemalePatient SafetyAdultmedicine.medical_specialtyPopulationChronic Liver Disease and CirrhosisClinical Trials and Supportive ActivitiesClinical SciencesImmunologyPlacebo03 medical and health sciencesDouble-Blind MethodClinical ResearchInternal medicineNAFLDmedicinenonalcoholic fatty liverHumanseducationAgedHepatologyGastroenterology & Hepatologybusiness.industryEvaluation of treatments and therapeutic interventionsOriginal Articlesmedicine.diseaseequipment and suppliesSurgeryCVC; NAFLD; NASH; inflammation; nonalcoholic fatty liver030104 developmental biologyinflammationHuman medicineSteatohepatitisbusinessDigestive DiseasesBiomarkers
researchProduct

Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer

2017

Abstract: Introduction: The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the development of genome-based personalized medicine. Fifteen to 20% of adenocarcinomas harbor an epidermal growth factor receptor (EGFR) activating mutation associated with responses to EGFR tyrosine kinase inhibitors (TKIs). Individual laboratories' expertise and the availability of appropriate equipment are valuable assets in predictive molecular pathology, although the choice of methods should be determined by the nature of the samples to be tested and whether the detection of only well-characterized EGFR mutations or rather, of all detectable mutations, is required.Areas covered:…

0301 basic medicineLung NeoplasmsEGFRDNA Mutational Analysis2734Real-Time Polymerase Chain Reactionmedicine.disease_causeBioinformaticsGenomePathology and Forensic Medicineresistance03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungGeneticsHumansMedicineEpidermal growth factor receptorLiquid biopsyLung cancerMolecular Biologycobas®Mutationliquid biopsybiologyReverse Transcriptase Polymerase Chain Reactionbusiness.industryMolecular pathologymedicine.diseaseTKIErbB Receptors030104 developmental biology030220 oncology & carcinogenesisCancer researchbiology.proteinMolecular Medicinecompanion diagnosticHuman medicineReagent Kits DiagnosticPersonalized medicinemutationbusinessCompanion diagnosticExpert Review of Molecular Diagnostics
researchProduct

Pharmacological basis of the anxiolytic and antidepressant properties of Silexan®, an essential oil from the flowers of lavender.

2021

Silexan®, a proprietary essential oil manufactured by steam distillation from Lavandula angustifolia flowers showed pronounced anxiolytic effects in patients with subthreshold anxiety disorders and was also efficacious in patients with Generalized Anxiety disorder (GAD). Moreover, evidences for antidepressant-like properties of Silexan® have been observed in anxious patients suffering from comorbid depressive symptoms and in patients with mixed anxiety-depression disorder (ICD-10 F41.2). In accordance with the clinical data Silexan® is active in several behavioral models in rodents at rather low concentrations indicating potent anxiolytic and antidepressive properties. As possible mechanism…

0301 basic medicineMAPK/ERK pathwayGeneralized anxiety disordermedicine.drug_classPregabalinFlowersPharmacologyAnxietyCREBAnxiolytic03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicinemedicineOils VolatileAnimalsHumansPlant OilsbiologyVoltage-dependent calcium channelChemistryDepressionCell Biologymedicine.diseaseCalcium Channel BlockersAntidepressive Agents030104 developmental biologyLavandulaMechanism of actionAnti-Anxiety Agentsbiology.proteinAntidepressantCalcium Channelsmedicine.symptom030217 neurology & neurosurgerymedicine.drugNeurochemistry international
researchProduct

Unexpected diversity in socially synchronized rhythms of shorebirds.

2016

The behavioural rhythms of organisms are thought to be under strong selection, influenced by the rhythmicity of the environment1,2,3,4. Such behavioural rhythms are well studied in isolated individuals under laboratory conditions1,5, but free-living individuals have to temporally synchronize their activities with those of others, including potential mates, competitors, prey and predators6,7,8,9,10. Individuals can temporally segregate their daily activities (for example, prey avoiding predators, subordinates avoiding dominants) or synchronize their activities (for example, group foraging, communal defence, pairs reproducing or caring for offspring)6,7,8,9,11. The behavioural rhythms that em…

0301 basic medicineMale0106 biological sciencesPeriodicityTime FactorsZygoteBehavioural ecologyCaptivityBiológiai tudományokEvolutionary ecology01 natural sciencesSEXUAL SELECTIONNesting BehaviorPredationCharadriiformesTermészettudományokNestPHYLOGENIESIncubationSocial evolution0303 health sciencesMultidisciplinaryROLESEcologyReproductionAnimal behaviourBiological EvolutionCircadian RhythmINCUBATION PATTERNSSexual selectionGEOLOCATOR DATACrypsisFemaleCIRCADIAN-RHYTHMSCuesPhotoperiodForagingNEST PREDATIONZoologyshorebirdsContext (language use)[SDV.BID]Life Sciences [q-bio]/BiodiversityEnvironmentBiology010603 evolutionary biologyCLOCKS03 medical and health sciencesRhythmSpecies SpecificityAnimals14. Life underwaterSensory cue030304 developmental biology[ SDV.BID ] Life Sciences [q-bio]/Biodiversity[ SDE.BE ] Environmental Sciences/Biodiversity and EcologyBIRDSFeeding BehaviorEVOLUTION030104 developmental biologyStarvationPredatory Behaviorsocially synchronized rhythmsta1181Evolutionary ecology[SDE.BE]Environmental Sciences/Biodiversity and Ecology
researchProduct

Sulfur amino acid restriction, energy metabolism and obesity

2021

Abstract Background Dietary sulfur amino acid (SAA) restriction is an established animal model for increasing lifespan and improving metabolic health. Data from human studies are limited. In the study outlined in this protocol, we will evaluate if dietary SAA restriction can reduce body weight and improve resting energy expenditure (REE) and parameters related to metabolic health. Method/design Men and women (calculated sample size = 60), aged 18–45 years, with body mass index of 27–35 kg/m2 will be included in a double-blind 8-week dietary intervention study. The participants will be randomized in a 1:1 manner to a diet with either low or high SAA. Both groups will receive an equal base di…

0301 basic medicineMaleAdipose tissuePhysiologyUrineOverweightMETHIONINE RESTRICTIONchemistry.chemical_compound0302 clinical medicineProtocolMedicine030212 general & internal medicineAmino AcidsRandomized Controlled Trials as TopicRISKPLASMARGeneral MedicineMiddle AgedAmino Acids SulfurADIPOSE-TISSUEVDP::Medisinske Fag: 700::Helsefag: 800Body CompositionCYSTEINEMedicineFemaleLIFE-STYLEmedicine.symptomAdultAdolescentMetabolic healthAdipose tissueSulfur amino acidsGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesYoung AdultHumansResting energy expenditureObesityPlasma biomarkersMethioninebusiness.industryRepeated measures designTranslational researchmedicine.diseaseObesityPREVENTIONDietary intervention030104 developmental biologychemistryCysteine restrictionGene expressionbusinessEnergy MetabolismBody mass indexJournal of Translational Medicine
researchProduct

Analysis of allergic immune responses in humanized mice.

2015

Nowadays, more than 25% of the population in industrial countries are affected by IgE-mediated (atopic) allergic diseases such as allergic rhinitis, asthma and atopic eczema. Due to intensive research on basis of in vitro studies with human immune cells and different murine in vivo models of allergy fundamental mechanisms of allergic immune responses have been elucidated during the last years. However, human studies are restricted and the immune system of mice differs from the human immune system in several aspects so that the transferability of experimental results from mice to men is limited. Humanized mice represent a new tool to analyze the interaction of human immune cells under physio…

0301 basic medicineMaleAllergyBiomedical ResearchImmunologyPopulationInflammationMice SCIDImmunoglobulin ET-Lymphocytes Regulatory03 medical and health sciencesMice0302 clinical medicineImmune systemHypersensitivityMedicineAnimalsHumanseducationAsthmaeducation.field_of_studyTransplantation Chimerabiologybusiness.industryImmunoglobulin Emedicine.diseaseIn vitroAsthmaDisease Models Animal030104 developmental biologyDesensitization ImmunologicHumanized mouseImmunologybiology.proteinFemalemedicine.symptombusiness030215 immunologyCellular immunology
researchProduct

Infant gut microbiota modulation by human milk disaccharides in humanized microbiome mice

2021

Human milk glycans present a unique diversity of structures that suggest different mechanisms by which they may affect the infant microbiome development. A humanized mouse model generated by infant fecal transplantation was utilized here to evaluate the impact of fucosyl-α1,3-GlcNAc (3FN), fucosyl-α1,6-GlcNAc, lacto-N-biose (LNB) and galacto-N-biose on the fecal microbiota and host–microbiota interactions. 16S rRNA amplicon sequencing showed that certain bacterial genera significantly increased (Ruminococcus and Oscillospira) or decreased (Eubacterium and Clostridium) in all disaccharide-supplemented groups. Interestingly, cluster analysis differentiates the consumption of fucosyl-oligosacc…

0301 basic medicineMaleBifidobacterium longuminfant fecal microbiotaMicrobiologiaRC799-869Gut floraAcetatesDisaccharidesFecesMice0302 clinical medicinelacto-n-biosefluids and secretionsRuminococcus gnavusRNA Ribosomal 16SEubacteriumgalacto-n–bioseBifidobacteriumbiologyGastroenterologyDiseases of the digestive system. Gastroenterologylacto-N-biosegalacto-N–biosefucosyl-α-1ButyratesInfectious Diseases030211 gastroenterology & hepatologyFemaleResearch ArticleResearch PaperMicrobiology (medical)AdultDNA Bacterialhumanized mouse modelInfants Malaltiesshort-chain fatty acidsMicrobiologyMicrobiology03 medical and health sciencesfucosyl-α-16-N-acetylglucosamineYoung AdultAnimalsHumans6-n-acetylglucosamineMicrobiomeBacteriaMilk HumanRuminococcusInfant NewbornInfantAkkermansiafucosyl-α-13-N-acetylglucosaminebiology.organism_classificationcytokinesGastrointestinal Microbiome3-n-acetylglucosamineMice Inbred C57BL030104 developmental biologyshort-chain fatty acidscytokineshuman milk oligosaccharides
researchProduct

Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.

2019

The aim of this manuscript is to discuss the viewpoint of the European Organisation for Research and Treatment of Cancer (EORTC) Gastric Cancer Taskforce and Japan Clinical Oncology Group (JCOG) Gastric Cancer Study Group on the current challenges in the multidisciplinary management of stage II-III gastric and gastro-oesophageal junction (GEJ) cancer. We seek to outline how these challenges are addressed in current trials of both groups. Key elements of future trials of EORTC and JCOG in this indication are described, and a joint vision on how multidisciplinary research of gastric and GEJ cancer patients should be organised is outlined. ispartof: EUROPEAN JOURNAL OF CANCER vol:124 pages:67-…

0301 basic medicineMaleCancer ResearchEsophageal NeoplasmsADJUVANT CHEMOTHERAPY0302 clinical medicineEUROPEAN ORGANIZATIONMultidisciplinary approachGastricPerioperativeStage (cooking)AdjuvantClinical OncologyMISMATCH REPAIR DEFICIENCYdigestive oral and skin physiologyGastro oesophageal junctionOPEN-LABELPrognosisJCOGhumanitiesEORTCOncology030220 oncology & carcinogenesisCLINICAL-RESEARCHFemaleImmunotherapyEsophagogastric JunctionRANDOMIZED PHASE-IILife Sciences & Biomedicinemedicine.medical_specialtyStage ii03 medical and health sciencesStomach NeoplasmsmedicineChemotherapyHumansNeoplasm StagingScience & Technologybusiness.industryPERIOPERATIVE CHEMOTHERAPYGeneral surgeryCancerADENOCARCINOMAPLUS OXALIPLATINmedicine.diseaseSurvival Analysisdigestive system diseases030104 developmental biologyNeoplasm stagingbusinessTRIAL DESIGNEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

2016

Background:This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC).Methods:Patients received 800-mg intravenous necitumumab (day 1; 2-week cycles), followed by oxaliplatin 85 mg m -2, folinic acid 400 mg m -2, and 5-fluorouracil (400 mg m -2 bolus then 2400 mg m -2 over 46 h). Radiographic evaluation was performed every 8 weeks until progression. Primary endpoint was objective response rate.Results:Forty-four patients were enrolled and treated. Objective response rate was 63.6% (95% confidence interval 47.8-77.6); complete response was observed in …

0301 basic medicineMaleCancer ResearchOrganoplatinum CompoundsLeucovorinPhases of clinical researchmedicine.disease_causeGastroenterology0302 clinical medicineadvanced colorectal cancerAntineoplastic Combined Chemotherapy ProtocolsClinical endpointNeoplasm MetastasisNecitumumabModified FOLFOX6Aged 80 and overnecitumumabAntibodies MonoclonalMiddle AgedOxaliplatinTreatment OutcomeOncologyFluorouracil030220 oncology & carcinogenesisFemaleKRASFluorouracilColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyEGFRNeutropeniamodified FOLFOX6Antibodies Monoclonal HumanizedDisease-Free SurvivalProto-Oncogene Proteins p21(ras)03 medical and health sciencesFolinic acidInternal medicinemedicineKRASHumansAdvanced colorectal cancerAgedbusiness.industrymedicine.diseaseSurvival AnalysisSurgeryOxaliplatinCancérologie030104 developmental biologyClinical StudybusinessNecitumumabBritish Journal of Cancer
researchProduct